DrugPatentWatch Database Preview
Details for Patent: 7,745,409
» See Plans and Pricing
Which drugs does patent 7,745,409 protect, and when does it expire?
Patent 7,745,409 protects LINZESS and is included in one NDA.
This patent has eighty-six patent family members in twenty-six countries.
Summary for Patent: 7,745,409
| Title: | Methods and compositions for the treatment of gastrointestinal disorders |
| Abstract: | The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. |
| Inventor(s): | Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA) |
| Assignee: | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 11/949,340 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,745,409 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 7,745,409
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Allergan | LINZESS | linaclotide | CAPSULE;ORAL | 202811-001 | Aug 30, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Allergan | LINZESS | linaclotide | CAPSULE;ORAL | 202811-002 | Aug 30, 2012 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,745,409
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 365174 | Start Trial | |||
| Austria | 477268 | Start Trial | |||
| Australia | 2004210161 | Start Trial | |||
| Australia | 2005222387 | Start Trial | |||
| Australia | 2009235993 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
